Biomaterials for Personalized Cell Therapy

Facklam, Amanda; Volpatti, Lisa R.; Anderson, Daniel G.

doi:10.1002/adma.201902005

Cited by 97 publications

(79 citation statements)

References 310 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[26,70,73,74] To accomplish the goals of precision medicine requires precision biomaterials: biomaterials designed with the biology of the individual patient in mind for eliciting desired and predictable outcomes. [75][76][77][78][79][80][81][82][83][84] This includes considering a patient's sex, age, and ancestry in developing a precision biomaterial.…”

Section: In Pursuit Of Precision Medicinementioning

confidence: 99%

Let's Talk About Sex—Biological Sex Is Underreported in Biomaterial Studies

James

Guerin

Allen

2020

Adv Healthcare Materials

View full text Add to dashboard Cite

Precision medicine aims to better individualize healthcare. It requires that biomaterials be designed for the physiological characteristics of a specific patient. To make this a reality, biomaterials research and development must address differences of biological sex. More specifically, biomaterials should be designed with properties optimized and appropriate for male and female patients. In analyzing research articles from seven prominent biomaterials journals, sex as a biological variable is missing from an overwhelming majority of in vitro biomaterial studies. From the survey, the reporting of the sex of primary cell cultures happened only 10.3% of the time. Contributing to this trend is that commercial vendors bias cell lines toward one sex or another by not disclosing information of cell line sex at the time of purchase; researchers do not communicate this pertinent information in published studies; and many journal policies have little to no requirements for reporting cell line characteristics. Omitting this valuable information leads to a gap in the understanding of sex‐specific cell‐biomaterial interactions and it creates a bias in research findings towards one sex or another. To curb this concerning trend and make precision biomaterials a reality will require the biomaterials field to “talk about sex” by reporting cell sex more broadly.

show abstract

Section: In Pursuit Of Precision Medicinementioning

confidence: 99%

Let's Talk About Sex—Biological Sex Is Underreported in Biomaterial Studies

James

Guerin

Allen

2020

Adv Healthcare Materials

View full text Add to dashboard Cite

show abstract

“…[ 137,188c ] Furthermore, given the low immunogenicity of endogenous cells, the patient‐derived cell‐based immunotherapy will encounter less aggressive immune rejection, leading to improved treatment efficacy. [ 239 ]…”

Section: Discussionmentioning

confidence: 99%

Cell‐Based Delivery Systems: Emerging Carriers for Immunotherapy

Wang

Ding

et al. 2021

Adv Funct Materials

View full text Add to dashboard Cite

Immunotherapy is leading a paradigm shift in the treatment of various diseases, including tumors, auto‐immune diseases, and infectious diseases. However, the limited response rate and systemic side effects significantly impede the clinical applications of immunotherapy. As natural carriers for proteins and molecules, cells with low immunogenicity and toxicity have attracted considerable attention for biomedical applications and have achieved encouraging progress especially in immunotherapy. The convergence of multiple disciplines has equipped cell‐based delivery systems with control over their spatiotemporal distribution to enhance treatment efficacy and reduce side effects. Here, an overview of the fundamentals and design principles of cell‐based delivery systems followed by a perspective that includes the most recent advances of various cells as delivery carriers, with a special focus on the implications of cell‐based delivery systems for immunotherapy is offered.

show abstract

“…In either case, cells need to be extracted from the body, cultured and processed ex vivo, and delivered back into the patient. Biomaterials can play a role in the culture, expansion, genome editing, quality control, and delivery of cell therapies (77). One type of cellular therapy that is actively being tested in the clinic, with FDA-approved products now in the market, is adoptive T cell immunotherapy.…”

Section: Biomaterials For the Development Of Ex Vivo Manufactured Cellular Therapiesmentioning

confidence: 99%

Integrating Biomaterials and Genome Editing Approaches to Advance Biomedical Science

Abdeen

Cosgrove

Gersbach

et al. 2021

Annu. Rev. Biomed. Eng.

View full text Add to dashboard Cite

The recent discovery and subsequent development of the clustered regularly interspaced short palindromic repeat (CRISPR)–CRISPR-associated (Cas) platform as a precise genome editing tool have transformed biomedicine. As these CRISPR-based tools have matured, multiple stages of the gene editing process and the bioengineering of human cells and tissues have advanced. Here, we highlight recent intersections in the development of biomaterials and genome editing technologies. These intersections include the delivery of macromolecules, where biomaterial platforms have been harnessed to enable nonviral delivery of genome engineering tools to cells and tissues in vivo. Further, engineering native-like biomaterial platforms for cell culture facilitates complex modeling of human development and disease when combined with genome engineering tools. Deeper integration of biomaterial platforms in these fields could play a significant role in enabling new breakthroughs in the application of gene editing for the treatment of human disease. Expected final online publication date for the Annual Review of Biomedical Engineering, Volume 23 is June 2021. Please see http://www.annualreviews.org/page/journal/pubdates for revised estimates.

show abstract

Biomaterials for Personalized Cell Therapy

Cited by 97 publications

References 310 publications

Let's Talk About Sex—Biological Sex Is Underreported in Biomaterial Studies

Let's Talk About Sex—Biological Sex Is Underreported in Biomaterial Studies

Cell‐Based Delivery Systems: Emerging Carriers for Immunotherapy

Integrating Biomaterials and Genome Editing Approaches to Advance Biomedical Science

Contact Info

Product

Resources

About